Bradycardia News and Research

RSS
Bradycardia, ("heart slowness"), as applied to adult medicine, is defined as a resting heart rate of under 60 beats per minute, though it is seldom symptomatic until the rate drops below 50 beat/min.
Endurance athletes at high risk of atrial fibrillation

Endurance athletes at high risk of atrial fibrillation

FDA approves Sagent Pharmaceuticals' labetalol HCl injection for severe hypertension

FDA approves Sagent Pharmaceuticals' labetalol HCl injection for severe hypertension

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

ZYPREXA RELPREVV approved by FDA

ZYPREXA RELPREVV approved by FDA

Montreal Heart Institute performs landmark procedure

Montreal Heart Institute performs landmark procedure

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Nonanesthesiologist-administered propofol for GI procedures safe

Nonanesthesiologist-administered propofol for GI procedures safe

Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

Bioniche Pharma acquires injectable drugs from Xanodyne Pharmaceuticals

BIOTRONIK launches its new, unified platform pacemaker series in Europe

BIOTRONIK launches its new, unified platform pacemaker series in Europe

Bradycardia more likely in patients taking cholinesterase inhibitors

Bradycardia more likely in patients taking cholinesterase inhibitors

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

Transoma Medical commences enrollment in its COMPLIANCE atrial fibrillation clinical trial

Transoma Medical commences enrollment in its COMPLIANCE atrial fibrillation clinical trial

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma markets preservative-free drugs for glaucoma

Multaq approved for atrial fibrillation by FDA

Multaq approved for atrial fibrillation by FDA

Children as young as five with life threatening anorexia

Children as young as five with life threatening anorexia

FDA approves Symbyax for treatment-resistant depression

FDA approves Symbyax for treatment-resistant depression

Aton Pharma acquires Timoptic product line from Merck & Co

Aton Pharma acquires Timoptic product line from Merck & Co

Sedative dexmedetomidine may offer advantages over agents often used for sedation in ICU

Sedative dexmedetomidine may offer advantages over agents often used for sedation in ICU

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia